Osteoporosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Osteoporosis Market Outlook

Thelansis’s “Osteoporosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteoporosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Osteoporosis Overview

Osteoporosis is a debilitating skeletal disease characterized by the degradation of bone tissue microarchitecture and the loss of bone mass. This condition significantly increases bone fragility, making individuals more susceptible to fractures. The intricate process of bone turnover, normally a delicate balance between resorption and formation, is disrupted in osteoporosis. Osteoclasts play a role in bone removal through acidification and proteolytic digestion, while osteoblasts contribute by secreting osteoids into the resorption cavity. Postmenopausal women face a heightened risk of osteoporosis due to a rapid increase in bone turnover, persisting for up to 40 years after the cessation of ovarian function, leading to progressive bone loss. A myriad of factors contribute to the development of osteoporosis, including smoking, low body mass index, inadequate nutrition, vitamin D deficiency, low dietary calcium intake, aging, gender, hormonal changes, previous fractures, family history of osteoporosis, menopause, certain medications, and other underlying health conditions. In the United States, the impact of osteoporosis is substantial, affecting approximately 10 million people aged over 50, with an additional 34 million individuals at risk. Early detection and timely treatment of osteoporosis yield positive outcomes. However, if left untreated, this condition can result in chronic pain and an increased risk of fractures. Mitigating the risk of osteoporosis involves:

• Adopting preventive measures such as using bisphosphonates.
• Engaging in regular exercise.
• Maintaining a calcium-rich diet.

These interventions contribute to bone health and play a crucial role in reducing the overall burden of osteoporosis on individuals and the healthcare system.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Osteoporosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034